Crinetics Receives FDA Approval for PALSONIFY

Crinetics Pharmaceuticals shares are trading higher after the company announced FDA approval of PALSONIFY, the first once-daily oral therapy for adults with acromegaly, marking a pivotal achievement in their treatment offerings.